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A B S T R A C T
Traumatic brain injury (TBI) poses a major public health problem on a global scale. Its burden results from high
mortality and signiﬁcant morbidity in survivors. This stems, in part, from an ongoing inadequacy in diagnostic
and prognostic indicators despite signiﬁcant technological advances. Traumatic axonal injury (TAI) is a key
driver of the ongoing pathological process following TBI, causing chronic neurological deﬁcits and disability.
The science underpinning biomarkers of TAI has been a subject of many reviews in recent literature. However, in
this review we provide a comprehensive account of biomarkers from animal models to clinical studies, bridging
the gap between experimental science and clinical medicine. We have discussed pathogenesis, temporal kinetics,
relationships to neuro-imaging, and, most importantly, clinical applicability in order to provide a holistic per-
spective of how this could improve TBI diagnosis and predict clinical outcome in a real-life setting. We conclude
that early and reliable identiﬁcation of axonal injury post-TBI with the help of body ﬂuid biomarkers could
enhance current care of TBI patients by (i) increasing speed and accuracy of diagnosis, (ii) providing invaluable
prognostic information, (iii) allow eﬃcient allocation of rehabilitation services, and (iv) provide potential
therapeutic targets. The optimal model for assessing TAI is likely to involve multiple components, including
several blood biomarkers and neuro-imaging modalities, at diﬀerent time points.
1. Introduction
Traumatic brain injury (TBI) is a global public health problem. It is
amongst the leading causes of mortality in young people in developed
countries [1], and many survivors of TBI suﬀer from chronic, persistent
disabilities. In the United States (US) alone, 1.7 million individuals
sustain a TBI every year, causing 52,000 deaths, and contributing to
approximately 30% of all injury-related deaths [2]. In Europe, the an-
nual incidence of TBI is estimated to be around 235 cases per 100,000
across 23 diﬀerent European countries, with an average mortality of 15
per 100,000 [3]. Furthermore, the incidence of TBI continues to rise
globally, and is predicted by the World Health Organisation (WHO) to
become one of the leading causes of death and disability by 2020.
Approximately 5.3 million victims of TBI in the US [4], and 7.7 million
in the European Union [3], live with disabilities resulting from the
initial traumatic injury. Indeed, TBI consists of both an acute insult and
delayed changes resulting in chronic disability. The clinical con-
sequences of the continuing pathological process is reﬂected by a range
of neurological, cognitive, and neuropsychiatric deﬁcits [5,6], with a
devastating impact on the patient’s quality of life and considerable cost
to the healthcare system as a result of its chronic and heterogeneous
nature. Cognitive and neuropsychiatric dysfunction post TBI is diverse,
including attentional deﬁcits [7], memory impairment [8], executive
dysfunction [9], defective emotional recognition [10], agitation [11],
depression [12], and language diﬃculties [13].
Amongst the key components of TBI pathophysiology is traumatic
axonal injury (TAI), sometimes referred to as diﬀuse axonal injury
(DAI) [14]. TAI is thought to contribute to the long-term manifestations
of TBI and its understanding could be vital for predicting outcomes. TAI
can aﬀect large white matter tracts of the brain, which play a key role in
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communication between neuroanatomically distinct regions, facil-
itating connectivity and the formation of large-scale networks. Whilst
axonal injury has long been appreciated on neuropathological ex-
amination of post TBI brains through observation of signs such as ax-
onal ‘retraction bulbs’, varicosities, and white matter damage [14–16],
understanding its functional eﬀect on networks in the brain in vivo has
yet to be fully explored. However, more recent advances in network
science and imaging have enabled visualization and analysis of the
large-scale structural and functional connectivity of the brain. The
‘default mode network’ and ‘salience network’ are examples of net-
works in the brain that have been extensively studied in the normal
healthy population, which provides a reference point for comparisons
in pathological disease states [17]. By studying the level of activity in
such networks, the severity and speciﬁc distributions of DAI have been
elegantly demonstrated to correlate with several cognitive impairments
seen post-TBI, including attention [18], memory [19], and executive
function [20] (for review see Sharp et al [17]).
Hence there is a need for additional clinical tools in the diagnosis
and prognosis of TAI. By understanding the mechanisms underlying
TAI, speciﬁc proteins released during axonal injury can be characterised
and measured, serving as biomarkers.
This can potentially aid patient healthcare by (i) increasing speed of
diagnosis in the acute setting owing to accessibility of potential ﬂuid
biomarker assays, (ii) improving accuracy of diagnosis since the short
half life of several biomarkers mean that they reﬂect a speciﬁc part of
the TBI process, (iii) providing more certainty to the outlook of victims
on their future quality of life, (iv) focusing rehabilitation services to
those with poorer prognostic indicators, and (v) providing potential
therapeutic targets (see review by Hill et al [21]). Such biomarkers may
exist in several bodily ﬂuids including CSF, blood, and saliva [22].
Extensive research has been carried on the use of biomarkers in TBI, but
there has been little appreciation for their use in the context of TAI.
From a clinical perspective, biomarkers can be any quantiﬁable
product serving as a marker of insult. This deﬁnition, however, does not
appreciate the direct pathophysiological link between the site and
nature of injury, and biomarker measured. For instance, there are
several biomarkers that may reﬂect TAI but cannot be realized con-
ceptually from a pathological perspective. Neuron speciﬁc enolase
(NSE), S-100B, and glial ﬁbrillary acidic protein (GFAP) are all ex-
amples of promising biomarkers for TBI [23]. GFAP, as the name sug-
gests, is of glial origin and shown to rise acutely in severe TBI, peaking
during the ﬁrst few days post injury before gradually decreasing, and
demonstrated to predict clinical outcome [24]. This was corroborated
by further evidence of the use of both serum S-100B, a calcium binding
protein found in Schwann cells and glia, and GFAP as successful diag-
nostic indicators of TBI severity [25]. NSE, an enzyme found in the
neuronal soma, along with S-100B and myelin basic protein (MBP),
could be used to predict outcomes in paediatric TBI [26]. Whilst all of
these biomarkers demonstrate clinical validity, their origins mean that
they share no direct conceptual link with the axon itself. Indeed, eva-
luation of biomarkers in this fashion results in a broad classiﬁcation of
direct and indirect biomarkers of axonal injury. In this review we will
focus on direct biomarkers of axonal injury because it facilitates an
explanation of eﬀect-causal relationships, and signiﬁes the meeting
point of basic scientiﬁc understanding and translation to the clinical
setting. For a more general account of the use of biomarkers in TBI,
please see the review by Kawata et al [27].
Fig. 1. Pathogenesis of TBI and the generation of biomarkers. Acceleration/ deceleration forces during TBI results in axonal undulations demonstrated above. Intra-
axonal calcium concentrations then rise due to (i) inﬂux from extracellular sources via transporters and due to mechanoporation, and (ii) intracellularly from
mitochondria under oxidative stress following injury. Increase in intracellular calcium then causes activation of calpains and caspases, which then contribute to
breakdown of: (i) myelin sheath, releasing MBP, (ii) neuroﬁlaments, releasing NF chains of varying weights, (iii) APP, releasing B amyloid peptides of various
weights, (iv) tau, a microtubule associated protein, into various fragments, and (v) spectrin, a cytoskeletal protein contributing to axonal morphology, into a
collection of products known as SBDP. Abbreviations: APP- amyloid precursor protein, MBP- myelin basic protein, NF- neuroﬁlaments, SBDP- spectrin breakdown
products, TBI- traumatic brain injury.
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2. Methods
A multi-database (PubMed, Embase, Web of Science) literature re-
view was performed between January 1980 and June 2017 for bio-
markers of TAI. Search terms included combinations of: “neuroﬁla-
ment”, “NF”, “NF-H”, “NF-L”, “myelin basic protein”, “MBP”, “tau
protein”, “tau fragments”, “amyloid”, “amyloid peptides”, “spectrin
breakdown products”, “spectrin”, “SBDP”, “traumatic brain injury”,
and “traumatic axonal injury”. All abstracts were reviewed for re-
levance to the chosen topic. Animal studies were assessed and included
in background sections. Clinical studies were evaluated with respect to:
(i) biomarkers, (ii) body ﬂuids, (iii) kinetics (iv) outcome measures, and
(v) ﬁndings. Pertinent ﬁndings were collated and each biomarker
evaluated in the following format: (i) background, (ii) clinical studies,
and (iii) kinetics.
3. Pathogenesis
Understanding of the pathogenesis of TAI at a cellular level un-
derpins the rationale of using biomarkers (see Fig. 1). The axon is a
slender projection from the neuronal soma that can extend over vast
distances and ultimately facilitates the immense connectivity of the
nervous system. Structural stability is provided by proteins such as
neuroﬁlaments, actin, and spectrin, whilst axonal transport occurs via
microtubules, supported by microtubule associated proteins (MAP)
such as tau protein.
There are several angles to consider in order to understand the
pathophysiological processes underlying brain response to head
trauma: (i) pattern of damage, (ii) cellular mechanisms of injury, (iii)
histopathological correlates of injury, and (iv) timescales of events.
3.1. Cellular mechanism of injury
Axonal injury can be divided into primary and secondary axotomy,
each resulting from distinct processes. Primary axotomy is mechanical
breakage of the axon resulting from forces transmitted from traumatic
impact. The mechanism involves initial disruption of the axonal
transport system, causing axonal retraction, and eventually leading to
axonal breakage, or axotomy [30]. However, primary axotomy is not
considered a major component of the pathological changes seen in TAI
[14,31].
Secondary axotomy, in contrast, is delayed, extensive, considerably
more complex, and likely to result in the clinical manifestations seen in
TAI. Rotational acceleration of the brain can cause stretching of white
matter axons, leading to a dysregulation in sodium and potassium in-
ﬂux and eﬄux, respectively, culminating in an increase in intracellular
calcium concentration [14,32]. The source of calcium inﬂux is multiple,
both from intracellular organelles and extracellular ﬂuid, and has
pleiotropic eﬀects within the neuron. One eﬀect involves stimulation of
two systems: calpain-mediated necrosis and caspase-mediated apoptosis
[33,34]. Animal models demonstrate that each has characteristic peaks
of proteolytic activity [35,36] but calpain-mediated proteolysis pre-
dominates in the initial phase of severe TBI and shown to result in
biomarker release during this phase when sampled in human CSF [37].
Proteolytic activity results in disruption of the axonal cytoskeleton
and degradation of structural proteins, such as spectrin [38], neuroﬁ-
laments [39], tau protein [40], and several others. Another eﬀect of the
raised intracellular calcium concentration is the disruption of mi-
tochondrial membrane stability, thus altering neuronal metabolism
[41] that is already under the strain of increased metabolic activity.
Ultimately, a simple mechanical trigger results in a cascade of structural
and metabolic insults. The subsequent axonal damage stimulates glu-
tamate release that results in unregulated NMDA receptor-mediated
excitation of surrounding neurons, causing further damage and ﬁnally
resulting in secondary axotomy [42].
3.2. Histopathological correlates
The two main histopathological ﬁndings associated with axonal
injury are axonal ‘retraction bulbs’ and varicosities [14,43]. Axonal
bulbs are thought to represent the culmination of processes that occur
during primary axotomy. Evidence shows that bulb formation occurs
due to interruption in the axonal transport system and subsequent ac-
cumulation of amyloid beta precursor protein at axonal endings [43].
This underlies the use of beta-amyloid as a histological marker of ax-
onal damage [44].
Whilst periodic axonal swellings, commonly referred to as var-
icosities, are also widely recognized as a hallmark of axonal injury, the
intracellular structural correlate that manifests in this ﬁnding had not
been clearly elucidated until recently. The process of TAI was visually
captured using transmission electron microscopy and im-
munohistochemical methods on an in vitro model of axonal injury [43].
This model demonstrated that acute injury manifests as axonal un-
dulations within two minutes, and later forms varicosities over the
course of a few hours. Interestingly, this breakage was only partial as
less than a third of microtubules in these focal regions were aﬀected.
Given the key role of microtubules in axonal transport, it follows that a
degree of transport can still occur uninterrupted. The more complex
mechanical forces inﬂicted on the brain during real-life TBI and the
anatomical milieu in which axons reside are likely to aﬀect the rate and
location of formation of these swellings. Indeed, this is evidenced by the
identiﬁcation of a combination of axonal undulations, swellings, and
bulbs in human acute severe TBI samples, suggesting the presence of
additional factors that require further studies.
4. Biomarkers of axonal injury
Although there is a scarcity of studies evaluating TAI speciﬁcally
with the use of sensitive imaging methods such as diﬀusion tensor
imaging and its correlation with biomarkers of TAI, there is still ex-
tensive research on the use of biomarkers in TBI. The following is a
review of the most prominent biomarkers arising from axonal origin:
neuroﬁlaments, MBP, tau protein, amyloid protein, and spectrin
breakdown products (SBDP). The fact that these biomarkers are ac-
cepted to arise directly from axons suggests that their elevation in TBI is
likely to be a reﬂection of the axonal component of TBI pathology and
thus an indirect reference to TAI. Therefore, we will review the litera-
ture on both TAI and TBI where relevant.
4.1. Neuroﬁlaments
4.1.1. Background
Neurons of the CNS contain type IV intermediate ﬁlaments, also
known as neuroﬁlaments (NF). These structures are approximately
10 nm in diameter, and are composed of an assembly of three chains: a
light chain (NF-L), an intermediate chain (NF-M), and a heavy chain
(NF-H), weighing 68 kDa, 150 kDa, and 190 to 210 kDa, respectively
[45]. It follows from the pathogenesis of TAI that NF chains may be
released after axonal damage and could serve as biomarkers of axonal
injury. This is supported by evidence of their release in the context of
axonal damage in multiple sclerosis and can be measured in various
biological ﬂuids [46], and altered expression in zebraﬁsh models of TBI
[47]. Phosphorylation of NF-H is speciﬁc to axons, forming the basis of
interest in the use of phosphorylated NF-H (pNF-H) as a biomarker of
axonal injury.
Both animal and human models of TBI support the involvement of
NF in axonal injury. Intraneuronal redistribution of NF-H and NF-L, and
colocalisation with beta-amyloid protein, has been demonstrated in
animal models of TBI [44]. Similarly, a rat model of impact acceleration
TBI correlated DTI measures of white matter damage with reduced le-
vels of NF-L on histopathological examination in selected regions of the
brain [48]. These ﬁndings are also reﬂected by serum levels of pNF-H in
S. Manivannan et al. Clinical Neurology and Neurosurgery 171 (2018) 6–20
8
early models of TBI in rats, which demonstrate a rise in serum pNF-H
levels that also correlates with severity of injury [49]. More recently,
serum and CSF levels of pNF-H were shown to correlate with severity of
mechanical impact in a Marmarou impact acceleration model in rats
[50]. Given existing evidence of this brain injury model correlating
with TAI in particular [51], these ﬁndings reinforce a more speciﬁc role
of NF-H in axonal injury. Also, post-mortem histopathological ex-
amination of the corpus callosum in human TBI brains showed reduced
levels of NF-H and NF-L proteins, and an increase in calpain-mediated
spectrin breakdown products [52], implying calpain-mediated proteo-
lysis of neuroﬁlaments in TAI. Taken together, there is considerable
evidence from histopathological, biological ﬂuid, and radiological
perspectives in animal studies to support the use of NF as a clinical
biomarker of axonal injury.
4.1.2. Clinical studies (see Tables 1 and 2)
NF was also utilised as a marker of TAI in clinical studies. One
retrospective study [53] assessed the use of serum NF-L as a prognostic
biomarker in TBI patients. Serum NF-L signiﬁcantly enhanced pre-
dictive capability when combined with other clinical and radiological
parameters. A more recent study [4] demonstrated that serum NF-L
distinguishes between controls and severe TBI cohorts and correlates
with 12 month GOS. Consistent with the previous study, it signiﬁcantly
enhanced the predictive capacity of existing models consisting of other
clinical parameters [55]. Also, an ultra-sensitive detection method, the
Simoa platform [56], with a lower detection limit for NF-L than the
conventional ELISA assay was used. It is possible that the limitations of
the ELISA assay in the ﬁrst study [53] contributed to the lack of a
signiﬁcant correlation between NF-L and TAI. This is supported by a
recent study [57], which clearly demonstrated that NF-L could distin-
guish between controls and severe TBI groups, with a signiﬁcant cor-
relation with DTI based measures of axonal white matter injury. Taken
together, there is evidence that serum NF-L can be used for diagnostic
purposes, as part of a prognostic model of TBI, and as an indicator of
severity of TAI, but further studies are required with appropriate
radiological modalities and more sensitive detection assays to assess the
role of NF-L in TAI more deﬁnitively.
Phosphorylated NF-H (pNF-H), similarly to NF-L, shows potential
for use as a biomarker of axonal injury. Serum pNF-H levels measured
on the second to fourth days post TBI were signiﬁcantly higher in pa-
tients with a poorer outcome at 6 months. Initial serum pNF-H was
higher in patients with evidence of TAI on initial CT scans [58]. Simi-
larly, serum pNF-H is signiﬁcantly higher in adults with mild TBI with
positive compared to negative CT scans [59]. Serum pNF-H at 24 h post
TBI could be used as a predictive marker of death at 6 months and levels
at 72 h post TBI could distinguish between unfavourable and favourable
GOS at 6 months [61],. Interestingly, median pNF-H was higher in the
TAI patients at all time points over a ten day period compared to the
focal group, but there was no diﬀerence between patients with ex-
pansive contusions and those without such lesions [62]. This supports
the theoretical assumption that a biomarker originating from the axonal
cytoskeleton would be further raised in TAI and highlights the danger of
assuming that biomarkers of axonal origin studied in the context of TBI
are necessarily similar to what would be seen with TAI. Nonetheless, it
is not unreasonable to postulate that whilst absolute levels may diﬀer
according to severity of axonal injury, the underlying trajectory may be
similar.
4.1.3. Kinetics (see Table 3)
Serum NF-L and pNF-H appear to follow similar trajectories in
clinical studies. Shahim et al. [54] recorded an acute rise in NF-L over
the ﬁrst 12 days post TBI with a peak at 12 days and a return to baseline
at 1 year follow up. However, it is unclear whether NF-L continues to
rise beyond 12 days and when exactly it returns to baseline. Animal
studies suggest that NF-L may continue to rise up to 3 weeks post injury
[63] but this requires corroboration in human studies. Rat models of
TBI reported a peak in serum pNF-H at 2 days, followed by a decline
over several days [64]. In human TBI, serum pNF-H rises acutely from 4
to 10 days post TBI but, again, its return to baseline is less clear [62].
Given the early evidence of temporal diﬀerences in accumulation of the
three NF chains in a swine model of TBI [39], further studies are ne-
cessary to clearly elucidate the kinetics of NF-L and pNF-H.
4.2. Myelin basic protein (MBP)
4.2.1. Background
White matter axons are surrounded by a myelin sheath produced by
oligodendrocytes centrally and Schwann cells peripherally. Whilst
myelin is mainly formed by both lipid and protein components, MBP
forms approximately 30% of the protein component. MBP has long been
associated with axonal injury and degeneration in several animal
models [65,66]. Furthermore, the diagnostic and prognostic potential
of serum MBP in head injury patients has been explored at a very early
stage [67]. CSF levels of MBP have been extensively studied in various
neurological pathologies in the paediatric population and shown to
correlate with clinical parameters [68,69]. Also, one early study [70]
showed that CSF levels of MBP measured in the ﬁrst week post TBI
correlated with GOS at 7 days, 3 months, and 6 months post injury. A
rat model of TBI demonstrated the proteolytic cleavage of MBP into
various smaller fragments detected by mass spectrometry [71], sup-
porting their potential use as biomarkers of axonal injury. Thus the
theoretical, clinical, and experimental background of MBP indicates its
potential utility as a biomarker of axonal injury.
4.2.2. Clinical studies (see Tables 1 and 2)
Zhang and colleagues [60] demonstrated that MBP, along with
other biomarkers, can be used to diﬀerentiate between controls and
severe TBI patients, survivors and non-survivors, and unfavourable and
favourable GOS at 6 months. Su et al. [72] demonstrated that CSF-MBP
could be used as diagnostic and prognostic indicator in paediatric vic-
tims of severe TBI by its ability to distinguish between controls and
severe TBI groups and between abusive and non-abusive trauma. This
latter ﬁnding is signiﬁcant as it suggests the potential for the use of MBP
from a forensic perspective, and corroborates earlier ﬁndings with
serum MBP [73]. Since myelination is a physiological process occurring
from infancy to adolescence [74], results from paediatric studies cannot
be applied to adults as they may diﬀer. Essentially, there is a lack of
recent studies focusing on the role of serum MBP in traumatic axonal
injury. This may be a result of the fact that MBP necessitates a severely
compromised blood brain barrier to be released into the serum in larger
amounts [75], and more sensitive detection assays have not been used
to study MBP as of yet.
4.2.3. Kinetics (see Table 3)
Serum MBP also rises in the acute phase of TBI, with detection as
soon as 1.5–8 h post injury [76] but remains elevated for up to two
weeks [67]. However, more studies are required to elucidate the exact
trajectory of MBP and its proteolytic processing in patients with TAI. In
conclusion, whilst MBP has been identiﬁed at a very early stage as a
potential axonal biomarker, little attempt has been made to use more
sensitive detection assays and to correlate serum levels with TAI in the
clinical setting.
4.3. Tau
4.3.1. Background
Tau protein is a MAP found in axons [77], weighing 48–68 kDa, and
playing multiple roles in maintaining the intraneuronal mileu including
axonal transport, cell signaling, and crosslinking microtubule networks
[78,79]. The latter function is of importance in traumatic axonal injury:
tau ultimately mediates the viscoelastic response to the rotational
forces that trigger axonal injury discussed earlier [14,80,81]. Indeed,
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Table 1
detailing ﬁndings from recent studies of biomarkers of axonal injury in patients with TBI.
Biomarker Biological ﬂuid Injury Findings Reference
pNF-H Blood Paediatric TBI • Serum pNF-H signiﬁcantly increased when DAI on initial CT• Days 2 to 4 serum pNF-H signiﬁcantly increased in GOS=1• Ratio of days 2 to 6 serum pNF-H and day 1 pNF-H signiﬁcantly diﬀerent between GOS=1 and
GOS > 1
[56]
DAI and focal TBI • Median serum pNF-H higher in DAI than focal TBI for 1 to 10 days post admission [59]
Mild TBI • Signiﬁcantly higher serum pNF-H on day 1 and 3 compared to control• Signiﬁcantly higher in CT+mild TBI patients• Signiﬁcant Inverse correlation between pNF-H and GCS
[57]
Severe TBI • All markers signiﬁcantly higher in TBI than controls• All markers signiﬁcantly higher in non-survivors than survivors, and unfavourable than favourable
GOS score
[69]
TBI • 24 h serum pNF-H predicts death at 6 months• 72 h serum pNF-H predicts unfavourable outcome
[58]
NF-L Blood TBI • NF-L combined with core parameters signiﬁcantly enhanced outcome prediction at 6-12 months [51]
Severe TBI • 24 h NF-L level separates severe TBI from control, and survivors from non-survivors, and predicts 12
month outcome
• Signiﬁcant correlation with CT Marshall score and pupil reactivity, but not GCS
[52]
Severe TBI/ DAI • Serum NF-L distinguishes TBI from controls• Higher serum NF-L correlates with lower FA
[55]
MBP Blood Severe TBI • Serum levels remain high for 2 weeks post injury• Day 2 to 6 serum MBP higher in poor outcome than good outcome
[64]
Paediatric TBI • Time to peak signiﬁcantly lower with non-abusive TBI• Time to peak correlated with GOS, VABS, and IQ at 6 months
[71]
CSF Paediatric severe TBI • Higher levels for 5 days after injury• Mean concentration lower if< 1 year old, and in abusive head trauma
[70]
Severe TBI • All markers signiﬁcantly higher in TBI than controls• All markers signiﬁcantly higher in non-survivors than survivors, and unfavourable than favourable
GOS score
[69]
Tau Blood Mild TBI • Weak correlation between 6 hour C-tau and 3 month RPCQ and post concussive syndrome• Non signiﬁcant predictor of 3 month post concussive syndrome
[89]
• Higher serum tau in TBI than controls (non signiﬁcant)• Could not discriminate post-concussive syndrome
[90]
• C-tau has no signiﬁcant correlation with head CT scan result or post-concussive syndrome [91]• Signiﬁcantly higher serum total tau post-concussion vs pre-season [94]• No diﬀerence in pre- and post-season serum tau-A• Serum tau-C signiﬁcantly higher post- vs pre-season• Serum tau-A correlates with severity of injury and return to play time
[83]
Self-reported TBI • Most participants sustained injury at least 18 months prior• Signiﬁcant positive correlation between T-tau levels and frequency of TBI, post-concussion syndrome
symptoms, and PTSD symptoms
• No correlation with severity of depression post TBI
[95]
TBI • Serum tau at<24 h and Day 30 post-TBI could separate cmTBI cohort from controls, with optimal
accuracy at< 24 h
• Signiﬁcant correlation with post-traumatic amnesia and with radiological measures of injury severity
[96]
CSF Head injury; DAI • Signiﬁcantly higher CSF C-tau levels in closed head injury vs neurological controls• Association between clinical status (GCS) and CSF c-tau levels
[86]
Severe TBI • Day 1 CSF C-tau higher in TBI than controls, and correlates with discharge GCS and GOS• Initial C-tau distinguishes favourable/ unfavourable GOS and normal/ raised ICP
[87]
• Tau signiﬁcantly higher in TBI than controls (dementia and headache)• Normal tau levels when CSF collected> 43d post trauma• Signiﬁcant negative correlation between time elapsed since head trauma and CSF collection• No correlation between tau and initial GCS or patient age
[117]
• Higher CSF tau in TBI than NPH controls• Correlation between initial CSF tau and 1 year GOSE• Distinguishes good vs bad GOSE, and mortality
[88]
(continued on next page)
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once the mechanical buﬀering capacity of tau is exceeded, axonal
stretch can destroy the organisation of microtubules [82] and set oﬀ the
cascade of events culminating in secondary axonal injury. The phos-
phorylation and proteolytic cleavage of tau protein following TBI is a
complex process involving several enzymes that can generate a range of
products that can aid neuronal function or possess neurotoxic proper-
ties [83]. Neurotoxic fragments may form a key component of neuro-
ﬁbrillary tangles seen in several neurodegenerative diseases [84], and
the C-terminal fragment of tau (C-tau) is one example of a neurotoxic
fragment seen in traumatic brain injury [85]. Recent evidence [86] that
hyperphosphorylated tau (P-tau) accumulates in several brain regions
associated with working memory in a mouse TBI model indicates that it
may also play a role in long term cognitive deﬁcits seen in TBI, high-
lighting its potential as a prognostic biomarker. There is also some
evidence for the use of tau protein as a blood biomarker of chronic
traumatic encephalopathy, a neurodegenerative condition occurring as
a consequence of repetitive mild TBI, in sportsmen [87].
4.3.2. Clinical studies (see Tables 1 and 2)
It has been established at an early stage that C-tau is a speciﬁc
marker of TBI when raised levels were found in the CSF of head injury
patients but not in other neurological pathologies or controls [88]. The
same group [89] then measured initial levels of C-tau in the CSF of
patients with severe TBI and compared it with clinical outcome mea-
sured by GOS at discharge. Not only was C-tau signiﬁcantly correlated
with clinical outcome, but was also superior to GCS in predicting GOS
at discharge. Whilst this early study lends some credibility to the use of
C-tau as a biomarker, it is not informative of the long-term outcome of
this patient cohort, which is a key aim of using biomarkers. However, a
later study [90] found that levels of tau protein in ventricular CSF on
days 2–3 post TBI distinguished between patients with favourable and
unfavourable 1 year outcomes measured by GOSE (Extended Glasgow
Outcome Scale). Thus there appears to be a diﬀerential role between
tau and products of tau cleavage in predicting outcome in TBI patients.
Evidence on the use of serum levels of tau protein and its fragments
as biomarkers in TBI have been mixed. Early studies [91,92] failed to
elucidate a signiﬁcant correlation between serum tau or C-tau and
clinical symptoms following mild TBI, although serum tau protein le-
vels were higher in patients compared to controls [92]. A later study
[93] measured C-tau in the blood of mild TBI patients but also found no
signiﬁcant correlation with initial head CT or self-reported outcome
measures. Larger sample size and more sensitive imaging methods may
reveal more about the role of C-tau in traumatic axonal injury. It is
possible that CSF levels are more apt than serum levels for its use as a
biomarker, and that it is better suited to prognostic indication in severe
TBI rather than mild TBI. However, it is diﬃcult to reconcile this pro-
position with existing knowledge regarding the generation of C-tau in
the underlying pathogeneic process. Indeed, with the advent of more
sensitive immunoassays for detection of tau proteins [94,95], more
positive results are emerging. A multicenter study [96] demonstrated
that professional ice hockey players had signiﬁcantly higher levels of
serum tau protein at all sampling times after concussion, extending as
far as 144 h post injury, than their preseason baseline. Also, 144-h
serum tau levels correlated with severity of post concussion syndrome,
and could be used to predict return to play. The fact that serum tau was
superior to neuron speciﬁc enolase and S-100B as a biomarker of con-
cussion in this study could be an indication of the importance of axonal
pathology in the constellation of symptoms seen in mild traumatic brain
Table 1 (continued)
Biomarker Biological ﬂuid Injury Findings Reference
Aβ peptides Blood Severe TBI • Measurements taken during ﬁrst week post TBI• Comparing TBI patients with controls: plasma Aβ42 signiﬁcantly higher• Comparing survivors and non-survivors: plasma Aβ42 signiﬁcantly lower
[119]
TBI in young military
personnel
• TBI cohort sustained injury on average 20.6 months prior• Signiﬁcantly increased Aβ40 and reduced Aβ42/Aβ40 ratio in TBI compared to controls• Aβ42 increased in TBI but non-signiﬁcant ﬁnding
[123]
TBI • Day 30 serum Aβ42 separates controls from cmTBI• Signiﬁcant correlation between Day 30 serum Aβ42 and clinical outcome at 6 months• No diﬀerence between severity of injury identiﬁed radiologically or post-traumatic amnesia
[96]
CSF Severe TBI • Signiﬁcantly lower levels of Aβ40, higher levels of Aβ42, and lower Aβ40/Aβ42 ratio in TBI compared
to controls
[115]
• Aβ42 signiﬁcantly lower than controls (headache and dementia) at all time points• No correlation between time since trauma and CSF collection time or with initial GCS• Signiﬁcant correlation with patient age• Signiﬁcant correlation between Aβ42 and GOS outcomes
[117]
• Collected within 72 h of TBI; higher levels of Aβ oligomers in patients with better outcome• Signiﬁcant correlation between CSF Aβ oligomers and GOS score and disability rating
[118]
• Measurements taken during ﬁrst week post TBI• Comparing TBI patients with controls: CSF Aβ42 signiﬁcantly lower• Comparing survivors and non survivors: CSF Aβ42 signiﬁcantly higher
[119]
αII SBDP Blood Mild TBI • Day 1 αII SNTF correlates with white matter changes in selected CNS tracts, impaired cognition at 3
months post injury, and recovery from cognitive deﬁcits
[130]
• Mean serum αII SNTF signiﬁcantly elevated at 1, 12, 36, 144 h post-concussion compared with
preseason baseline, but unchanged after concussion-free training
• Serum αII SNTF returned to baseline at the time of return to play• 36 h serum αII SNTF distinguishes between<6 and>6 days return to play
[131]
CSF Severe TBI • αII SBDP signiﬁcantly increased compared to controls at many time points• 12 h SBDP150/145 levels correlate with severity of injury, CT results, and outcome at 6 months
[129]
• Median AUC and maximum concentration for SBDP150 and SBDP145 signiﬁcantly greater in patients
with static or worsening GCS scores than improving GCS scores at 24 h post injury
• Positive correlation between number of hours of raised ICP and AUC for all αII SBDP
[35]
Abbreviations: Aβ- amyloid beta protein, A-tau- tau fragment, AUC- area under the curve, cmTBI- complicated mild traumatic brain injury, CNS- central nervous
system, CSF- cerebrospinal ﬂuid, CT- computed tomography, C-tau- C-terminal tau fragment, DAI- diﬀuse axonal injury, FA- fractional anisotropy, GCS- Glasgow
coma scale, GOS- Glasgow outcome scale, GOSE- extended Glasgow outcome scale, ICP- intracranial pressure, IQ- intelligence quotient, MBP- myelin basic protein,
NF-L- light neuroﬁlament chain, pNF-H- phosphorylated heavy neuroﬁlament chain, NPH- normal pressure hydrocephalus, RPCQ- Rivermead Post Concussion
Symptoms Questionnaire, SBDP- spectrin breakdown products, SNTF- spectrin N-terminal fragment, TBI- traumatic brain injury, T-tau- total tau, VABS- Vineland
Adaptive Behaviour Scales.
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Table 2
detailing clinical use of biomarkers of axonal injury following TBI, all ﬁndings include blood biomarkers except where indicated.
Time since injury Injury Biomarker Clinical Indication Statistics References
1 h Mild TBI (sport-related
concussion)
T-tau Diagnosing sport related concussion (by comparing post concussion 1 h r T-
tau with post friendly game T-tau)
AUC: 0.80
95% CI: 0.65-0.94
[94]
Diagnosing post concussive syndrome lasting more than 6 days AUC: 0.91
95% CI: 0.81-1.00
Tau Diagnosing sport-related concussion AUC: 0.74
95% CI: 0.61-0.86
[131]
< 6 h Severe TBI pNF-H Prediction of unfavourable outcome at 6 months post injury Cut-oﬀ: 833.3 pg/
mL
Sensitivity: 83.3%
Speciﬁcity: 61.1%
AUC: 0.759
P-value: 0.056
[69]
Prediction of death at 6 months post injury Cut-oﬀ: 940.4 pg/
mL
Sensitivity: 75.9%
Speciﬁcity: 74.4%
AUC: 0.815
P-value: 0.202
MBP Prediction of unfavourable outcome at 6 months post injury Cut-oﬀ: 15.6 μg/mL
Sensitivity: 70.8%
Speciﬁcity: 66.7%
AUC: 0.781
P-value: 0.135
[69]
Prediction of death at 6 months post injury Cut-oﬀ: 16.9 μg/mL
Sensitivity: 69.0%
Speciﬁcity: 80.8%
AUC: 0.805
P-value: 0.176
Tau Prediction of unfavourable outcome at 6 months post injury Cut-oﬀ: 303.2 pg/
mL
Sensitivity: 79.3%
Speciﬁcity: 79.3%
AUC: 0.808
P-value: 0.212
[69]
Prediction of death at 6 months post injury Cut-oﬀ: 282.9 pg/
mL
Sensitivity: 81.2%
Speciﬁcity: 72.2%
AUC: 0.782
P-value: 0.119
12-36 h Mild TBI SNTF Diagnosing post-concussive syndrome lasting longer than 6 days AUC: 0.87
95% CI: 0.79-0.96
[131]
< 24 h TBI Tau Distinguishing cmTBI from controls AUC: 0.9013 [96]
24 h Mild TBI pNF-H Categorising CT- and CT+mild TBI patients Cut oﬀ: 110.5 pg/
mL
Sensitivity: 100%
Speciﬁcity: 100%
P-value: 0.0001*
[57]
Severe TBI NF-L Separates survivors from non-survivors Cut oﬀ: 411 pg/mL
Sensitivity: 71%
Speciﬁcity: 88%
LR+: 6.0
[52]
Separating patients with favourable (GOS 1-3) and unfavourable (GOS 4-5)
outcome
Cut-oﬀ: 216 pg/mL
YI: 0.38
Sensitivity: 83%
Speciﬁcity: 56%
LR+: 1.9
Separating severe TBI patients from controls Cut oﬀ: 24.0 pg/mL
YI: 0.96
Sensitivity: 97%
Speciﬁcity: 96%
LR+: 23.0
GCS=/<13 pNF-H Prediction of death at 6 months post injury Cut-oﬀ: 240 pg/mL
AUC: 0.930
[58]
36 h Mild TBI SNTF Diagnosing sport-related concussion AUC: 0.76
95% CI: 0.63-0.90
[131]
Diagnosing sport-related concussion that delayed return to play for at least
6 days
AUC: 0.85
95% CI: 0.73-0.97
48 h Paediatric TBI pNF-H Prediction of unfavourable outcome (GOS=1) Cut oﬀ: 117.1 μg/L
Sensitivity: 71.4%
Speciﬁcity: 83.8%
AUC: 0.764
P-value: 0.028*
[56]
(continued on next page)
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Table 2 (continued)
Time since injury Injury Biomarker Clinical Indication Statistics References
48-72 h Severe TBI T-tau (CSF) Prediction of mortality Cut oﬀ: 2126 pg/
mL
Sensitivity: 100%
Speciﬁcity: 81.5%
AUC: 0.934
[88]
Discriminating between good (GOSE 1-4) and bad (GOSE 5-8) outcomes at
1 year
Cut oﬀ: 702 pg/mL
Sensitivity: 83.3%
Speciﬁcity: 69%
AUC: 0.814
< 72 h Severe TBI Aβ oligomers
(CSF)
Prediction of poor outcome at 6 months AUC: 0.8750
95% CI: 0.698-
1.053
[118]
72 h Mild TBI pNF-H Categorising CT- and CT+mild TBI patients Cut oﬀ: 77.5 pg/mL
Sensitivity: 100%
Speciﬁcity: 96.43%
P-value: 0.0001*
[57]
GCS=/<13 Prediction of unfavourable outcome (vegetative state or death) at 6 months
post injury
Cut-oﬀ: 80 pg/mL
AUC:?
[58]
144 h
(Day 6)
Mild TBI T-tau Diagnosing post concussive syndrome lasting more than 6 days AUC: 0.76
95% CI: 0.58-0.94
[94]
Day 30 TBI Tau Distinguishing cmTBI from controls AUC: 0.8225 [96]
Aβ42 AUC: 0.8362
>18 months Self-reported TBI T-tau Identiﬁcation of self-reported TBI AUC: 0.74
95% CI: 0.61-0.68
P-value: 0.007
[95]
Identiﬁcation of sustaining 3 or more TBI AUC: 0.73
95% CI: 0.61-0.86
P-value: 0.003
Identiﬁcation of medically validated TBI AUC: 0.69
95% CI: 0.51-0.89
P-value: 0.007
Time independent Severe TBI Aβ42 (CSF) Prediction of poor outcome (GOS1-3) Cut oﬀ: 230 pg/mL
Sensitivity: 100%
Speciﬁcity: 82%
[117]
Abbreviations: Aβ- amyloid beta protein, AUC- area under curve, CI- conﬁdence interval, cmTBI- complicated mild traumatic brain injury, CSF- cerebrospinal ﬂuid,
CT- computed tomography, GCS- Glasgow coma scale, GOS- Glasgow outcome scale, GOSE- extended Glasgow outcome scale, LR- likelihood ratio, MBP- myelin basic
protein, NF-L- light neuroﬁlament chain, pNF-H- phosphorylated heavy neuroﬁlament chain, SNTF- spectrin N-terminal fragment, TBI- traumatic brain injury, T-tau-
total tau, YI- Youden’s index.
Table 3
detailing kinetic proﬁle of biomarkers of axonal injury following TBI.
Biomarker Injury/ model Biological ﬂuid Kinetics Reference
pNF-H TBI- DAI and focal Blood Serum NF-H increases from day 4 to day 10 [59]
• 0.263 – 1.325 ng/L in DAI• 0.103 – 1.108 ng/L in focal
NF-L TBI Upward trend over course of 14 days [51]
Severe TBI Signiﬁcantly higher levels than control for ﬁrst 12d, peak at 12d, and normalised over course of 1y [52]
Aβ42 TBI Blood Signiﬁcantly elevated for up to 90 days post TBI with a peak at 30 days [96]
Severe TBI Signiﬁcant elevation at all time points during ﬁrst week post TBI [119]
Severe TBI CSF Signiﬁcant reduction on Day 1 and 3, and Day 5–7 during initial week post-TBI [119]
Tau Mild TBI Blood Peak during ﬁrst hour post concussion, signiﬁcant decline in following 12 h, and non-signiﬁcant reductions from
12 to 144 h
[94]
TBI Signiﬁcantly elevated for up to 90 days post TBI with a peak at< 24 h followed by a decline over following 90
days
[96]
Severe TBI CSF In two patients with poor outcome (GOS-2 and 3): peak between Day 5 and 15 post-TBI followed by decline,
normalises by Day 43
[117]
C-tau Severe TBI CSF Initial peak and decline over ﬁrst 3 days [87]
A-tau, Mild TBI Blood Tau-A peaked at 12 h post concussion (non signiﬁcant), [83]
αII SBDP Severe TBI CSF SBDP150 and SBDP145 peak at 6 h and remain elevated during ﬁrst 24-72 h; SBDP120 elevated at all time points
except 24 h post injury
Half life of SBDP150, SBDP145, and SBDP120 was 24, 23, and 40 h respectively
[35]
Marker elevation: SBDP150 up to 24 h, SBDP145 up to 72 h, and SBDP120 at all time points except 24 h post
injury
[129]
Abbreviations: Aβ- amyloid beta protein, A-tau- tau fragment, CSF- cerebrospinal ﬂuid, C-tau- C-terminal tau fragment, DAI- diﬀuse axonal injury, GOS- Glasgow
outcome scale, NF-H- heavy neuroﬁlament chain, NF-L- light neuroﬁlament chain, pNF-H- phosphorylated heavy neuroﬁlament chain, SBDP- spectrin breakdown
products, TBI- traumatic brain injury.
S. Manivannan et al. Clinical Neurology and Neurosurgery 171 (2018) 6–20
13
injury. A later study by the same group [85], studied the use of tau
fragments for the same purpose, and found that A-tau, another product
of proteolytic cleavage of tau protein, correlated both with duration of
clinical symptoms and predicting safe return to play.
Olivera et al. [97] assessed the relationship between plasma con-
centrations of T-tau and both TBI and its sequelae in military personnel.
The study model involved a TBI cohort deﬁned by self-reported mea-
sures of TBI, of which over a third had medical evidence of TBI, and
matched controls. The majority of self-reported TBI participants had
sustained injury at least 18 months prior. Signiﬁcant positive correla-
tions were found between T-tau concentrations and frequency of TBI,
post-concussion syndrome symptoms, and post traumatic stress dis-
order symptoms but not severity of depression. Whilst these ﬁndings
demonstrate the potential utility of T-tau as a biomarker of injury and
neuro-cognitive deﬁcit following TBI, the lack of medically diagnosed
TBI in the TBI cohort suggests that further research is required for va-
lidation of the ﬁndings. Indeed, individuals of the self-reported TBI
group with accompanying medical evidence of TBI displayed a sig-
niﬁcantly higher serum T-tau concentration than the self-reported
group alone.
A more recent study [98], assessing GFAP, Aβ42, and tau protein,
demonstrated a diagnostic and prognostic role for plasma levels of tau
protein in patients with TBI. Both< 24 h and Day 30 post TBI serum
levels were capable of separating complicated mild TBI (cmTBI) cohort
from controls, with optimal accuracy at< 24 h. Whilst the other bio-
markers measured also distinguished between these groups, the tra-
jectory of plasma tau protein over 90 days also diﬀered between cmTBI
and moderate TBI cohorts, with the former group showing a steady
decline from initial time points to 90 days and the latter group re-
maining equally elevated for up to 30 days before declining at 90 days.
The prognostic utility of plasma tau was demonstrated by its correlation
with both post-traumatic amnesia and radiological measures of injury
severity.
Taken together, existing evidence on the use of tau protein is en-
couraging but further work is required to (i) compare CSF and serum
levels of total tau and tau fragments during TBI, and observe any dif-
ferences in their trajectories, (ii) use more sensitive imaging modalities
for axonal injury such as MRI and DTI to assess correlation with tau
protein, and (iii) elucidate the relationship between tau and long term
neurocognitive outcomes in TAI assessed by neuropsychological tools.
Future avenues include the use of tau as a therapeutic target, evidenced
by one study [99] demonstrating a possible attenuation in the patho-
logical eﬀects of diﬀuse axonal injury in a rat model by reducing loss of
tau protein, and other studies [100,101] blocking P-tau in animal TBI
models to prevent pathological sequelae of the disease.
4.3.3. Kinetics (see Table 3)
Shahim et al [96] measured a peak in serum total tau concentrations
at 1 h post concussion and a signiﬁcant drop at 12 h followed by per-
sistent elevation compared to baseline until 144 h post injury. One
study [98] demonstrated an acute rise in tau protein< 24 h post injury
and a decline over the following 90 days, but remained signiﬁcantly
elevated at all time points. This suggests that serum tau rises earlier
than other axonal biomarkers of traumatic injury, which may be a re-
ﬂection of its role as a mechanical buﬀer whose threshold is crossed to
inﬂict axonal injury. Tau fragments show a diﬀerent pattern [85] with
A-tau peaking at 12 h post injury, although this was not signiﬁcantly
diﬀerent to other time points up to 144 h, and C-tau was signiﬁcantly
elevated following injury compared to baseline but not demonstrating
any visible peak. This delay between total tau and tau fragments may
reﬂect underlying processes such as proteolytic cleavage and sub-
sequent release into the bloodstream.
4.4. Amyloid protein
4.4.1. Background
Amyloid precursor protein (APP) accumulates predominantly as a
result of disruption to axonal transport after trauma [102], although
there is also extensive evidence of increased expression of the APP gene
following TBI [103–105,102,106–108]. The two major isoforms of
amyloid β (Aβ) yielded by proteolytic cleavage of APP are Aβ42 and
Aβ40. Although Aβ peptides are regarded as a physiological component
of human interstitial ﬂuid [109], potentially released as a by-product of
neuronal metabolism [110], cytotoxic properties have been attributed
to the aggregation of Aβ into an insoluble form. The relevance of Aβ to
axonal injury is exempliﬁed by a recent study involving post-mortem
examination of patients who had previously undergone surgical leu-
cotomy for the treatment of schizophrenia and survived for a minimum
of 40 years after the procedure [117]. The procedure involves the bi-
lateral severance of axons in the prefrontal cortex, providing an ex-
cellent model of severe axonal damage in ‘iatrogenic’ TBI. Neuro-
pathological examination demonstrated evidence of white matter
damage and a combination of P-tau and Aβ accumulation in the grey
matter surrounding the site of axonal injury, which was both speciﬁc to
the site of injury and absent in matched, non-leucotomised controls.
These ﬁndings are particularly relevant due to their similarities to pa-
thological signs seen in CTE, and supports the current theory that CTE is
a result of chronic axonal damage occurring post-TBI.
Aβ has been extensively studied as a marker of neuronal injury in
several diﬀerent contexts. Concentrations of Aβ are altered in severe
brain injury in a wide range of biological environments including brain
tissue and extracellular ﬂuid [118–120]. Notably, CSF Aβ has been
referred to as a ‘state marker’ of Alzheimer’s disease due to its corre-
lation with AD pathology [121,122]. Taken together, these studies
demonstrate that Aβ peptides are promising candidates for use as bio-
markers of axonal injury in TBI.
4.4.2. Clinical studies (see Tables 1 and 2)
The use of amyloid-related proteins, such as APP and Aβ, as clinical
biomarkers of TBI is supported by several early studies demonstrating
changes in CSF concentrations following TBI [123,124]. In addition,
there was early evidence that CSF Aβ42 levels correlated signiﬁcantly
with clinical outcome following TBI, but no correlation with clinical
status at admission [125,126]. Mondello et al [127] studied the re-
lationship between severe TBI and Aβ42 levels measured in both CSF
and plasma. Irrespective of biological ﬂuid, Aβ42 levels distinguished
severe TBI patients from controls, and survivors from non-survivors.
However, an interesting diﬀerence in the dynamics between CSF and
plasma measurements was demonstrated: Aβ42 was signiﬁcantly lower
in CSF and signiﬁcantly higher in plasma when the TBI cohort was
compared to controls, and when non-survivors were compared to sur-
vivors. Two theories may reconcile these ﬁndings: (i) reduced CSF le-
vels may reﬂect amyloid plaque deposition, and (ii) compromised blood
brain barrier resulting in release of Aβ42 into the bloodstream with a
concomitant decrease in CSF. There is increasing evidence to support
the latter hypothesis as blood brain barrier compromise has been linked
to clinical outcome following TBI [128]. Neither CSF nor plasma levels
of Aβ42 were capable of diﬀerentiating between focal lesions and dif-
fuse injuries identiﬁed on CT, which is inconsistent with studies de-
monstrating raised extracellular ﬂuid concentration of Aβ42 following
diﬀuse brain injury on cerebral microdialysis [120,129]). This raises
signiﬁcant questions regarding the use of Aβ42 as a marker of traumatic
axonal injury. It is possible that this simply reﬂects a biological en-
vironment dependent diﬀerence, as interstitial ﬂuid sampling is thought
to be a more focal representation of biomarker dynamics whilst CSF is
considered more global [130]. Alternatively, it could be a result of the
inadequacy of CT in identiﬁcation of diﬀuse brain injury.
A cross-sectional study of young military personnel with a history of
deployment-related TBI [131] evaluated the role of serum Aβ42 and
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Aβ40 as markers of chronic neurological status. Participants with a
positive history of TBI were assigned to the TBI cohort, with a mean
period of 20.6 months since injury. Compared to matched controls, the
TBI cohort demonstrated a signiﬁcantly increased Aβ40 concentration
and signiﬁcantly reduced Aβ42/ Aβ40 ratio. Whilst Aβ42 was increased
in the TBI cohort, this ﬁnding was non-signiﬁcant. Considering Aβ as a
key pathological feature of neurodegeneration, the relationship de-
monstrated between Aβ and TBI highlights the persistent neuronal in-
jury that outlasts the acute traumatic insult. Furthermore, the increased
incidence of depression, post-traumatic stress disorder, and post-con-
cussion syndrome in the TBI cohort suggests a potential role for Aβ in
the prediction or diagnosis of cognitive deﬁcits following TBI, although
no direct relationship was found in this study.
A recent study measured GFAP, tau, and Aβ42 proteins in the serum
of TBI patients at< 24 h, 30 days, and 90 days post trauma [98]. Both
the diagnostic and prognostic potential of Aβ42 was demonstrated by
(i) the use of day 30 serum Aβ42 to separate controls from cmTBI,
deﬁned as GCS > 13 on admission with evidence of brain injury on CT
scan, and (ii) a signiﬁcant correlation between day 30 serum Aβ42 and
clinical outcome at 6 months post injury measured by GOSE scores.
However, Aβ42 could not distinguish between diﬀerent severities of
injury measured radiologically or the presence of post-traumatic am-
nesia. Taken together, Aβ peptides appear to be optimal for use in the
sub-acute or chronic stages of TBI as a long-term prognostic indicator.
More studies with sensitive neuroimaging modalities for detection of
DAI are required to correlate Aβ more deﬁnitively with axonal injury in
the clinical setting.
4.4.3. Kinetics (see Table 3)
One study [98] demonstrated that Aβ42 is elevated for up 90 days
post TBI and peaks at 30 days, in contrast to more acute biomarkers.
This conﬂicts with prior evidence [127] of a signiﬁcant reduction in
CSF Aβ42 at several time points, and a signiﬁcant elevation in plasma
Aβ42 at all time points during the initial week. More studies are re-
quired to elucidate the trajectory of diﬀerent Aβ peptides during the
initial phase of TBI, and ﬁnd a coherent explanation for the diﬀerences
in concentration and temporal changes between CSF, plasma, and in-
terstitial ﬂuid for each.
4.5. Spectrin breakdown products
4.5.1. Background
Spectrin is widely known as a structural protein that helps maintain
cell shape and membrane integrity [132] and α-II spectrin fulﬁlls this
role as a component of the axolemmal cytoskeleton. The breakdown of
α-II spectrin after axonal injury has been elucidated, and involves the
calpain (calpain-1, calpain-2) and caspase (caspase-3) systems [34].
The protein is cross-linked and sequestered in the cristae of swollen
mitochondria, as a consequence of the calcium inﬂux in traumatic ax-
onal injury, prior to cleavage by spectrin protease. This process is
augmented by the cytochrome c release by the damaged mitochondria
[133]. This results in the generation of spectrin breakdown products
(SBDP). A recent study [134] demonstrated the involvement of spectrin
in disrupting axonal transport mechanisms in a rat optic nerve stretch
model, implicating its contribution to the secondary axotomy process
described earlier. Also, another study [135] elucidated the breakdown
of βII-spectrin under various conditions in in vitro cell culture and in
vivo rat models in an attempt to recapitulate the neurotoxic environ-
ment created by TBI. Again, SBDP fragments, more speciﬁcally βSBDP,
were found to correlate with calpain or caspase mediated proteolysis.
Neuropathology of human and swine models of both mild and severe
TBI demonstrate that SBDP does correlate with axonal injury, but
suggests a more heterogeneous nature to axonal injury than the existing
gold standard model with APP [136].
4.5.2. Clinical studies (see Tables 1 and 2)
There have been numerous studies on levels of SBDP in CSF of pa-
tients with TBI. Indeed, studies [37,137] have demonstrated raised le-
vels of SBDP generated by calpain-mediated proteolysis (SBDP-150 and
SBDP-145) in the CSF of patients with severe TBI. Furthermore, its di-
agnostic and prognostic potential is demonstrated by its correlation
with severity of injury and 6 month GOS [137]. The role of serum
spectrin N-terminal fragment (SNTF) as a biomarker of axonal injury
and outcomes in mild TBI patients was demonstrated by a seminal
paper [138]. Here, plasma SNTF samples at a median 14 h post injury
were raised in a subset of mild TBI patients but not in controls. The key
ﬁnding was that, when participants were stratiﬁed as SNTF positive or
negative, the former group showed signiﬁcant changes in the corpus
callosum and uncinate fasciculus on DTI, which was performed within
96 h of injury. Furthermore, cognitive deﬁcits were apparent from
various neuropsychological tests at 4-days, 1-month, and 3-months post
injury in the SNTF positive group. The same group [139] also demon-
strated the application of SNTF to predicting post concussion symptoms
in professional ice hockey players, further supporting its role as a
prognostic indicator. The fact that initial serum SNTF correlates with
both imaging and long term cognitive tests of axonal injury in patients
with initial CT negative scans provides strong evidence that biomarkers
are key in helping build a prognostic model for TBI that is currently
lacking.
4.5.3. Kinetics (see Table 3)
CSF studies show that diﬀerent SBDP fragments may have diﬀerent
temporal proﬁles. Brophy et al [37] eﬀectively characterised the tra-
jectory of both calpain (SBDP-150, SBDP-145) and caspase (SBDP-120)
mediated SBDP in the CSF of severe TBI patients. Whilst all fragments
increased within 6 h of injury, which correlates with in vitro models of
calpain activity in TBI [140], SBDP-150 and -145 peak at 34 h and re-
main elevated for 24–72 h but SBDP-120 peaks at 56 h and remains
elevated for up to 5 days. However, more studies are required to elu-
cidate the trajectory of SBDP in serum following TBI. In summary, SBDP
are promising when compared to other existing biomarkers of axonal
injury as they (i) provide a window for observing the unfolding of
diﬀerent mechanisms of pathogenetic processes in TAI, (ii) serve as a
prognostic indicator in TBI, and (iii) correlate with axonal injury in
neuropathological specimens. One major drawback of SBDP, however,
is the high expression of spectrin in erythrocytes [141], which impacts
its speciﬁcity as a blood biomarker of axonal injury.
5. Neuroimaging for TAI diagnosis
In the clinical setting, CT is the most rapid, safe, and accessible
option for evaluating TBI [142], providing valuable information on
focal injuries and intracranial bleeding that may necessitate immediate
neurosurgical intervention [143,144]. Whilst CT can identify severe
TAI through the presence of smaller haemorrhagic lesions, its ability to
identify ﬁne lesions associated with TAI is lacking [145]. Conventional
MRI is more capable of detecting these subtler lesions and white matter
damage [146] but is lacking in practical feasibility in the acute setting.
Indeed, there is extensive evidence of post-mortem examination of TBI
brains demonstrating signs of axonal injury that was undetected by
prior neuroimaging [147–150]. Therefore, both CT and low resolution
MRI are suboptimal for identiﬁcation of the TAI spectrum [151,152]
Diﬀusion tensor magnetic resonance imaging (DTI) is a non-invasive
and sensitive method of assessing white mater structure and integrity.
DTI measures the direction of diﬀusion of water molecules, meaning it
can exploit the unidirectional ﬂow of water along normal white matter
tracts to diﬀerentiate it from the disorganization seen in white matter
pathology, measured by a reduction in fractional anisotropy (FA) [153].
Such changes on DTI have been correlated with traumatic axonal and
white matter injury on histopathological studies in animal models of
TBI [154–156,48,157] and with long-term cognitive deﬁcits in human
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TBI patients [158–162]. Furthermore, recent evidence demonstrated a
correlation between levels of tau protein measured in cerebral micro-
dialysis samples by sequential ELISA methods and FA measures on DTI
in patients with severe TBI [163]. Drawbacks of DTI include diﬃculty
of access in the acute phase of TBI and a limited number of times for
usage [164]. Also, there is still a degree of uncertainty with interpreting
FA since comparison of DTI and histological ﬁndings in a rat TBI model
suggest that the reactive gliosis occurring with brain injury contributes
to an increase in FA [165], which questions the ﬁdelity of the re-
lationship between white matter and FA.
Another imaging modality based on DTI is diﬀusion tensor tracto-
graphy (DTT), which allows a three dimensional appreciation of central
nervous system (CNS) tracts [166–168], and is of growing interest in
the context of TAI [169]. Indeed, several studies have demonstrated its
use in detecting lesions in many CNS tracts including the corticospinal
tract, spinothalamic tract, medial lemniscus, fornix, and cingulum
[170–175]. A recent case study [176] demonstrated the utility of DTT
in identifying pathological correlates of delayed neurological symptoms
following mild TBI. For example, identiﬁcation of damage to spi-
nothalamic tracts explained abnormal pain sensation experienced by
the patient. The fact that DTT detected damage to various CNS tracts
that correlated with clinical ﬁndings when MRI ﬁndings were negative
underscores the insuﬃciency of existing imaging modalities and the
eﬃcacy of more advanced methods. Taken together with the prior
pathophysiological discussion of TAI, this study demonstrates the use of
tractography in identifying the speciﬁc neuroanatomical locations of
secondary axonal injury that correspond to clinical ﬁndings. Whilst this
is a huge step forward, there are several practical limitations with re-
spect to incorporating such imaging modalities into a routine health-
care setting.
One major drawback of DTI based imaging is that it measures dif-
fusion based on a Gaussian distribution model, when this is not always
the case in the brain [177], and is limited in evaluating white matter
with more complex ﬁber conﬁgurations [178]. High angular resolution
diﬀusion imaging (HARDI) modalities have been designed to circum-
vent this [179]. A recent study [180] used HARDI to assess patients
with mild traumatic brain injury. Despite imaging being performed on
average 21.2 days post injury, a signiﬁcant correlation between FA and
clinical outcome at 3–6 months was found in a cohort of mild TBI pa-
tients that experienced less than 24 h post traumatic amnesia. Although
the results are applicable to a limited cohort of TBI patients, the fact
that imaging performed beyond the acute stage of injury could predict
future outcomes is an encouraging prospect.
Susceptibility weighted imaging (SWI), is an imaging modality of
increasing interest due to its ability to discern traumatic axonal pa-
thology through identiﬁcation of associated traumatic microbleeds
[181], and showing superiority over other existing imaging methods
[182,183]. Given the evidence of potential relationships between spe-
ciﬁc characteristics of traumatic microbleeds and clinical outcome in
patients, this MRI sequence may be an eﬀective modality for identifying
TAI. Indeed, there is recent evidence demonstrating relationships be-
tween lesions in the mesencephalic region identiﬁed with SWI and
clinical outcomes in patients with DAI [184]. Thus, continuing devel-
opments in imaging modalities and varied approaches to image analysis
highlight the key role of neuroimaging in TAI.
6. Conclusion
Taken together, there are several angles to the clinical conundrum
of TAI. An ideal model for diagnosing, managing, and predicting out-
come of TAI would include several tools incorporating the strengths of
each individual component for optimal function. Although large num-
bers would be required to deduce this information, international re-
search groups such as CENTER-TBI [185] and TRACK-TBI [186] are
already gathering large data sets with which to achieve this. Also,
several studies have addressed the advantages of combining several
diﬀerent biomarkers to optimize prediction models rather than relying
on a single biomarker [60,98]. The practical issues associated with the
use of advanced imaging modalities such as DTI and DTT for assessing
TAI in an acute clinical setting suggests that it would be better suited to
a longer term assessment of outcome after the acute stage has passed.
The ideal TAI model would use body ﬂuid biomarkers for immediate
triage of patients, providing an indicator of those that require further
radiological assessment and follow up. Based on this indication, pre-
liminary CT and/or MRI imaging could be arranged appropriately for
the short term, and DTI or DTT for longer term prognosis.
Furthermore, biomarker measurements at diﬀerent time points (see
Fig. 2) could enhance prognostic information that would be of beneﬁt
to clinicians for planning further management and for victims in pro-
viding a more deﬁnitive picture of their condition. By correlating
Fig. 2. Summarises timepoints following TBI at which serum biomarkers (unless stated as CSF) can yield useful clinical information. For details of whether this is of
prognostic or diagnostic use, and which severity of TBI, see Table 3. Abbreviations: Aβ- amyloid beta protein, CSF- cerebrospinal ﬂuid, MBP- myelin basic protein,
NF-L- light neuroﬁlament chain, pNF-H- phosphorylated heavy neuroﬁlament chain, SNTF- spectrin N-terminal fragment, TBI- traumatic brain injury, T-tau- total
tau.
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biomarker measurements with neuroanatomical sites of axonal injury
on neuroimaging, patients at risk of speciﬁc neuro-cognitive deﬁcits
could be notiﬁed, and arrangements made accordingly. The next step
would be the use of biomarkers to monitor potential treatment strate-
gies targeting pathways leading to their generation and thus making the
transition from accurately informing patients of their condition to being
able to oﬀer therapeutic solutions.
In this review we have explored some of the existing major bio-
markers of axonal injury and their role in TAI. There are several other
biomarkers that have been extensively studied, such as GFAP, NSE, S-
100B, and upcoming biomarkers such as various miRNAs (see review by
Kawata et al [27]. Whilst they are all of relevance to TBI, we aimed to
provide a concise review of biomarkers of axonal origin in traumatic
injury to evaluate their role in TAI and also in TBI, since it is likely that
their release is a result of axonal injury even when the diagnosis is less
speciﬁcally labeled as TBI. This proposition is supported by evidence
such as the relationship between extracellular concentrations of tau
protein on cerebral microdialysis and FA on DTI in patients with severe
TBI [163], and the inadequacy of routinely used neuroimaging mod-
alities to detect axonal injury suggests that it is highly likely that a
multifaceted approach will be required. However, there are still several
issues regarding the discussed axonal biomarkers: (i) the temporal re-
lationship of biomarker concentrations in extracellular ﬂuid in cerebral
microdialysis, CSF, and serum; (ii) their relationships with FA measures
on DTI, and the reliability of a method of correlating this with TAI; (iii)
the long-term trajectory of these biomarkers; and, (iv) the optimal
model for diagnostic and prognostic purposes in TAI/TBI, and the
combination of biomarkers and clinical parameters this would involve.
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